Skip to main content

Indivior Pharmaceuticals

Indivior plc is a British specialty pharmaceutical company dedicated to developing innovative medicines to treat substance use disorders and opioid addiction. The company researches, manufactures, and distributes pharmaceutical products, prominently featuring Suboxone (buprenorphine and naloxone) and Sublocade (buprenorphine extended-release) for treating opioid use disorder, alongside treatments for alcohol use disorder and overdose rescue. Its core operations encompass pharmaceutical research, clinical trial management, regulatory compliance, and global commercial distribution. Revenue is derived primarily from the commercial sales of its addiction treatment drugs to healthcare providers, hospitals, and government agencies worldwide. Indivior holds a leading global market position in addiction treatment pharmaceuticals. The company is headquartered in Richmond, Virginia, United States, with legal domicile in Dublin, Ireland, and its ordinary shares trade on the London Stock Exchange and the Nasdaq Global Select Market.

5 of the funds FundTelligence covers report a position in Indivior Pharmaceuticals.

Legal name
Indivior Pharmaceuticals Inc
Sector
Health Care
Country
United Kingdom
Funds holding it
5
Exposure themes
Addiction, Mental Health, Psychiatry

Funds holding Indivior Pharmaceuticals

Loading...